|View printer-friendly version|
|May 13, 2007 1:45 p.m.|
|Teva Comments about the acquisition of generic business of Merck KGaA|
Jerusalem, Israel, May 13, 2007 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that, as the global market leader in generic pharmaceuticals, Teva is constantly evaluating opportunities to maximize shareholder value, including looking at potential acquisitions. Teva's long-held practice is to only pursue transactions that fit our long-term strategy of delivering profitable growth and enhancing our global leadership position while meeting our stringent financial criteria. While Merck's generics business would have been a strategic fit for Teva in certain regards the terms of this opportunity did not fully meet our investment criteria.